AG
Artal Group Portfolio holdings
AUM
$930M
This Quarter Return
-18.28%
1 Year Return
-3.57%
3 Year Return
+157.23%
5 Year Return
+160.22%
10 Year Return
+1,359.85%
AUM
$2.29B
AUM Growth
+$2.29B
(-27%)
Cap. Flow
-$77.6M
Cap. Flow
% of AUM
-3.38%
Top 10 Holdings %
Top 10 Hldgs %
70.19%
Holding
122
New
8
Increased
14
Reduced
14
Closed
21
Top Buys
| 1 |
Neumora Therapeutics
NMRA
|
$39.5M |
| 2 |
Apellis Pharmaceuticals
APLS
|
$23.4M |
| 3 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$12.3M |
| 4 |
IMGN
Immunogen Inc
IMGN
|
$11.8M |
| 5 |
Sagimet Biosciences
SGMT
|
$8.14M |
Top Sells
| 1 |
Krystal Biotech
KRYS
|
$41.1M |
| 2 |
SAGE
Sage Therapeutics
SAGE
|
$23.5M |
| 3 |
MoonLake Immunotherapeutics
MLTX
|
$20.4M |
| 4 |
Relay Therapeutics
RLAY
|
$15.2M |
| 5 |
Protagonist Therapeutics
PTGX
|
$13.8M |
Sector Composition
| 1 | Healthcare | 55.33% |
| 2 | Consumer Discretionary | 43.57% |
| 3 | Technology | 0.62% |
| 4 | Communication Services | 0.2% |
| 5 | Real Estate | 0.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
CAVA Group
CAVA
$7.83B
| $980M | 42.04% | 32,007,990 | – | – |
|
2
Lexicon Pharmaceuticals
LXRX
$400M
| $128M | 5.49% | 117,553,284 | – | – |
|
|
MRTX
3
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $88.2M | 3.78% | 2,024,226 -30,955 | -2% | -$1.35M |
|
|
ONC
4
BeOne Medicines Ltd. American Depositary Shares
ONC
$36.4B
| $72.7M | 3.12% | 403,934 -8,562 | -2% | -$1.54M |
|
5
Revolution Medicines
RVMD
$7.1B
| $70M | 3% | 2,529,737 +128,120 | +5% | +$3.55M |
|
6
Scholar Rock
SRRK
$3.14B
| $64.3M | 2.76% | 9,059,507 | – | – |
|
|
7
Apellis Pharmaceuticals
APLS
$3.48B
| $63.3M | 2.71% | 1,664,572 +614,505 | +59% | +$23.4M |
|
8
Amicus Therapeutics
FOLD
$2.34B
| $49.4M | 2.12% | 4,062,567 -500,000 | -11% | -$6.08M |
|
|
MORF
9
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $49M | 2.1% | 2,138,188 -1,807 | -0.1% | -$41.4K |
|
10
Cytokinetics
CYTK
$4.23B
| $44.7M | 1.92% | 1,518,831 +102,800 | +7% | +$3.03M |
|
|
SWTX
11
DELISTED
SpringWorks Therapeutics
SWTX
| $42M | 1.8% | 1,816,620 | – | – |
|
|
12
Neumora Therapeutics
NMRA
$280M
| $39.5M | 1.7% | +2,802,702 | New | +$39.5M |
|
|
CERE
13
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
| $35.8M | 1.53% | 1,638,858 | – | – |
|
|
SLRN
14
DELISTED
ACELYRIN
SLRN
| $25.1M | 1.08% | 2,469,279 +648,065 | +36% | +$6.59M |
|
15
Kymera Therapeutics
KYMR
$2.95B
| $25.1M | 1.08% | 1,805,346 | – | – |
|
|
SLN
16
Silence Therapeutics
SLN
$227M
| $24.6M | 1.05% | 2,500,000 +800,000 | +47% | +$7.86M |
|
|
IMGN
17
DELISTED
Immunogen Inc
IMGN
| $24M | 1.03% | 1,512,113 +746,616 | +98% | +$11.8M |
|
|
IGMS
18
DELISTED
IGM Biosciences
IGMS
| $21.1M | 0.9% | 2,522,244 | – | – |
|
19
Kura Oncology
KURA
$686M
| $18.4M | 0.79% | 2,018,056 | – | – |
|
|
AGEN
20
Agenus
AGEN
$133M
| $17.7M | 0.76% | 15,631,235 | – | – |
|
21
Sea Limited
SE
$110B
| $17.4M | 0.75% | 397,000 +47,000 | +13% | +$2.07M |
|
22
Denali Therapeutics
DNLI
$2.23B
| $16.6M | 0.71% | 802,899 | – | – |
|
|
KLRS
23
Kalaris Therapeutics, Inc. Common Stock
KLRS
$76.3M
| $14.2M | 0.61% | 6,597,167 | – | – |
|
24
Schrodinger
SDGR
$1.44B
| $14.1M | 0.61% | 500,000 -200,000 | -29% | -$5.65M |
|
25
Ventyx Biosciences
VTYX
$171M
| $14.1M | 0.6% | 405,239 -3,280 | -0.8% | -$114K |
|